Matinas BioPharma (NYSEAMERICAN:MTNB) Posts Earnings Results

Posted by Brenda Bartman on Mar 29th, 2024

Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.03) earnings per share (EPS) for the quarter, Yahoo Finance reports.

Matinas BioPharma Price Performance

Shares of MTNB traded down $0.02 on Friday, reaching $0.27. The company’s stock had a trading volume of 1,217,731 shares, compared to its average volume of 2,114,206. The firm has a market capitalization of $58.88 million, a PE ratio of -2.26 and a beta of 1.52. Matinas BioPharma has a twelve month low of $0.11 and a twelve month high of $0.89.

Institutional Investors Weigh In On Matinas BioPharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Private Advisor Group LLC boosted its holdings in Matinas BioPharma by 59.7% in the 1st quarter. Private Advisor Group LLC now owns 239,494 shares of the company’s stock valued at $192,000 after purchasing an additional 89,553 shares during the period. BlackRock Inc. raised its position in Matinas BioPharma by 0.7% in the 1st quarter. BlackRock Inc. now owns 4,325,053 shares of the company’s stock worth $3,479,000 after purchasing an additional 29,643 shares during the period. Atria Wealth Solutions Inc. purchased a new position in shares of Matinas BioPharma in the first quarter valued at about $32,000. State Street Corp increased its position in shares of Matinas BioPharma by 8.0% in the first quarter. State Street Corp now owns 712,471 shares of the company’s stock valued at $573,000 after acquiring an additional 52,897 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Matinas BioPharma in the second quarter valued at about $73,000. Hedge funds and other institutional investors own 11.77% of the company’s stock.

About Matinas BioPharma

(Get Free Report)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.